(Source: MediciNova Inc) LA JOLLA, Calif., July 24, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of 'fibrosis' which includes a broad range of fibrosis / fibrotic disease in different organs due to different causes. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier...
↧